Press Release: EURORDIS’ 2nd Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies

Boston, MA, February 2017 /PRNewswire/ -- Mapi, leading global health research and pharmaceutical service provider, will feature one of its top experts at EURORDIS' 2nd Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies this February 22-23, 2017.

Mapi Group's Xavier Fournie, MD - Corporate Medical Director, will hold the role of Rapporteur for Breakout Session #1  – Emerging options: Quality Data Generation / Pan-European disease & product registries to address needs of all stakeholders on Day 2 - Thursday, 23 February 2017 from 09.00 – 11.00 am.

This Symposium on improving patient access to rare disease therapies will bring together patient advocates, payers, HTA bodies, academics, clinicians, policy makers, investors and industry representatives. It will enable participants to understand the interests and challenges of each stakeholder group, to discuss current and emerging initiatives and to continue to work together to improve patients’ access to rare disease therapies.

Learn more at https://mapigroup.com/eventcalendar/2nd-multi-stakeholder-symposium-improving-patient-access-rare-disease-therapies/.

“Xavier brings a great deal of medical expertise is only second to his commitment and experience in supporting the development of Rare Disease treatments” commented Nigel Page, President & Chief Operating Officer, Real World Evidence.

About Mapi: Patients are at the heart of our research

Mapi Group has over 40 years of experience supporting Life-Science companies in developing and implementing strategies for commercializing novel treatments through Strategic Regulatory Services, Pharmacovigilance,  Market Access, Language Services, and gathering Real-World Evidence on Pharmaceuticals, Biologicals, and Medical Devices. Mapi Group is the premier provider of Health Research and Commercialization services to Life-Science companies enabling Market Authorization, Market Access and Market Adoption of novel therapeutics.  Visit http://www.mapigroup.com for more information

Press contact: Media@mapigroup.com

SOURCE: Mapi Group

###